Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer’s Disease

Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

(2013) Aaron H. Burstein et al.   CLINICAL NEUROPHARMACOLOGY

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease

(2013) Jaren W. Landen et al.   CLINICAL NEUROPHARMACOLOGY

Enhanced Proteolytic Clearance of Plasma A  by Peripherally Administered Neprilysin Does Not Result in Reduced Levels of Brain A  in Mice

(2013) J. R. Walker et al.   JOURNAL OF NEUROSCIENCE

Biomarkers for Alzheimer's: the sequel of an original model

(2013) Giovanni B Frisoni et al.   LANCET NEUROLOGY

Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial

(2013) Richard Dodel et al.   LANCET NEUROLOGY

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Plasma tau levels in Alzheimer's disease

(2013) Henrik Zetterberg et al.   Alzheimers Research & Therapy

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline

(2012) Alain Koyama et al.   ARCHIVES OF NEUROLOGY

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease

(2012) Henrik Zetterberg   ARCHIVES OF NEUROLOGY

Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer’s disease

(2012) Karl Herholz   Biomarkers in Medicine

Proficiency testing programs for Alzheimer’s disease cerebrospinal fluid biomarkers

(2012) Niklas Mattsson et al.   Biomarkers in Medicine

Reference measurement procedures for Alzheimer’s disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42

(2012) Niklas Mattsson et al.   Biomarkers in Medicine

Plasma biomarkers for Alzheimer’s disease: much needed but tough to find

(2012) Chantal Bazenet et al.   Biomarkers in Medicine

Gantenerumab for the treatment of Alzheimer's disease

(2012) Julien Delrieu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Immunotherapy for Alzheimer’s disease: from anti-β-amyloid to tau-based immunization strategies

(2012) Francesco Panza et al.   Immunotherapy

Neutralization of Soluble, Synaptotoxic Amyloid   Species by Antibodies Is Epitope Specific

(2012) W. Zago et al.   JOURNAL OF NEUROSCIENCE

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis

(2012) Reisa Sperling et al.   LANCET NEUROLOGY

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

(2012) Bengt Winblad et al.   LANCET NEUROLOGY

Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases

(2012) Carmen Noelker et al.   Molecular Diagnosis & Therapy

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

(2012) Thorlakur Jonsson et al.   NEW ENGLAND JOURNAL OF MEDICINE

TREM2 Variants in Alzheimer's Disease

(2012) Rita Guerreiro et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: Results of a pilot study

(2012) Jeffrey Randall et al.   RESUSCITATION

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

(2011) Niklas Mattsson et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Tau-targeted treatment strategies in Alzheimer's disease

(2011) Jürgen Götz et al.   BRITISH JOURNAL OF PHARMACOLOGY

Interacting with γSecretase for Treating Alzheimer's Disease: From Inhibition to Modulation

(2011) F. Panza et al.   CURRENT MEDICINAL CHEMISTRY

Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease: Cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden — Regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials

(2011) Maria Isaac et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease

(2011) Sherry L. La Porte et al.   JOURNAL OF MOLECULAR BIOLOGY

The Second-Generation Active A  Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects

(2011) C. Wiessner et al.   JOURNAL OF NEUROSCIENCE

Robust Central Reduction of Amyloid-  in Humans with an Orally Available, Non-Peptidic  -Secretase Inhibitor

(2011) P. C. May et al.   JOURNAL OF NEUROSCIENCE

Believe it or not: how much can we rely on published data on potential drug targets?

(2011) Florian Prinz et al.   NATURE REVIEWS DRUG DISCOVERY

Brain imaging in the study of Alzheimer's disease

(2011) Eric M. Reiman et al.   NEUROIMAGE

A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

(2010) Ronald S. Black et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Pittsburgh Compound-B and Alzheimer’s Disease Biomarkers in CSF, Plasma and Urine: An Exploratory Study

(2010) M. Degerman Gunnarsson et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients

(2010) Henrik Zetterberg et al.   EUROPEAN NEUROLOGY

PET imaging of brain amyloid in dementia: a review

(2010) Harriet Quigley et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Thinking Outside the Box: Alzheimer-Type Neuropathology That Does Not Map Directly Onto Current Consensus Recommendations

(2010) Peter T. Nelson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Circulating neprilysin clears brain amyloid

(2010) Yinxing Liu et al.   MOLECULAR AND CELLULAR NEUROSCIENCE

Biomarkers in Alzheimer's disease drug development

(2010) Kaj Blennow   NATURE MEDICINE

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

(2010) Harald Hampel et al.   NATURE REVIEWS DRUG DISCOVERY

Can Alzheimer disease be prevented by amyloid-β immunotherapy?

(2010) Cynthia A. Lemere et al.   Nature Reviews Neurology

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

‘Too much good news’ – are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease?

(2010) Kathleen R. Zahs et al.   TRENDS IN NEUROSCIENCES

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

(2009) Leslie M. Shaw et al.   ANNALS OF NEUROLOGY

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?

(2009) Å. K. Wallin et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity

(2009) Kajsa Sämgård et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal

(2009) John Hardy   JOURNAL OF NEUROCHEMISTRY

A  Immunotherapy: Intracerebral Sequestration of A  by an Anti-A  Monoclonal Antibody 266 with High Affinity to Soluble A 

(2009) K. Yamada et al.   JOURNAL OF NEUROSCIENCE

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

(2009) Pieter Jelle Visser et al.   LANCET NEUROLOGY

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Natural human antibodies to amyloid beta peptide

(2008) Paul Szabo et al.   AUTOIMMUNITY REVIEWS

The Brain Injury Biomarker VLP-1 Is Increased in the Cerebrospinal Fluid of Alzheimer Disease Patients

(2008) J.-M. Lee et al.   CLINICAL CHEMISTRY

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

(2008) Lars Lannfelt et al.   LANCET NEUROLOGY

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

(2008) Norman R. Relkin et al.   NEUROBIOLOGY OF AGING

Neuropathological Aspects of Alzheimer Disease, Parkinson Disease and Frontotemporal Dementia

(2008) Kurt A. Jellinger   Neurodegenerative Diseases